LINC00113: A Drug Target / Disease Biomarker (G54088)

Target Name: LINC00113

NCBI ID: G54088

LINC00113

Other Name(s): SLERCC | NCRNA00113 | C21orf23 | Long intergenic non-protein coding RNA 113 | long intergenic non-protein coding RNA 113

LINC00113: A Drug Target / Disease Biomarker

LINC00113 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a key regulator of cell growth and differentiation, and has been identified as a potential drug target for various diseases.

LINC00113 is a transmembrane protein that is composed of four intracellular domains: an N-terminal transmembrane domain, a coiled-coil domain, a regulatory domain, and an C-terminal T-spine domain. The N-terminal transmembrane domain is responsible for the protein's ability to enter the cell membrane and for its ability to interact with other proteins. The coiled-coil domain is responsible for the protein's ability to change shape and to play a role in cell signaling. The regulatory domain is responsible for the protein's ability to regulate gene expression, and the C-terminal T-spine domain is responsible for the protein's structural stability.

LINC00113 is a key regulator of cell growth and differentiation. It is involved in the regulation of cell proliferation, cell migration, and cell adhesion. LINC00113 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most promising aspects of LINC00113 as a drug target is its ability to modulate the activity of other proteins. LINC00113 has been shown to interact with a wide range of proteins, including transcription factors, signaling molecules, and cytoskeletal proteins. This makes it a potential target for drugs that can modulate the activity of these proteins and improve treatment outcomes for various diseases.

LINC00113 has also been shown to play a role in the regulation of cellular signaling pathways. LINC00113 has been shown to interact with the protein p53, a transcription factor that is involved in the regulation of gene expression and cell survival. This interaction between LINC00113 and p53 suggests that LINC00113 may be a useful target for drugs that can modulate the activity of p53 and improve treatment outcomes for various diseases.

Another promising aspect of LINC00113 as a drug target is its ability to modulate the activity of the immune system. LINC00113 has been shown to interact with the protein PDGF-R, a cytoskeletal protein that is involved in the regulation of cell growth and differentiation. This interaction between LINC00113 and PDGF-R suggests that LINC00113 may be a useful target for drugs that can modulate the activity of PDGF-R and improve immune function.

In conclusion, LINC00113 is a protein that has been identified as a potential drug target for various diseases. Its ability to modulate the activity of other proteins and play a role in the regulation of cellular signaling pathways and immune function makes it a promising target for future drug development. Further research is needed to fully understand the role of LINC00113 as a drug target and to develop effective treatments for various diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 113

The "LINC00113 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00113 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets